iptacopan
Novartis builds case for iptacopan as oral rival to PNH injectables
Phil Taylor
Alexion, AstraZeneca, Haematology, iptacopan, Novartis, paroxysmal nocturnal haemoglobinuria, Soliris, Ultomiris
0 Comment
Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial
Phil Taylor
Alexion, AstraZeneca, iptacopan, Novartis, paroxysmal nocturnal haemoglobinuria, rare disease, Soliris, Ultomiris
0 Comment
News/ News/ News/ R&D/ Sales and Marketing
Revamped Novartis highlights top R&D programmes at management update
Phil Taylor
iptacopan, Kisqali, Novartis, Pluvicto, R&D, remibrutinib, Sales and Marketing, Scemblix, strategy
0 Comment
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Phil Taylor
C3 glomerulopathy, complement therapeutics, iptacopan, nephrology, Novartis, rare disease
0 Comment
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Phil Taylor
Alexion, complement therapeutics, EHA 2021, Haematology, iptacopan, Novartis, rare disease, Soliris, Ultomiris
0 Comment